Paradigm Therapeutics
www.paradigm-therapeutics.comParadigm Therapeutics was founded in 1999 and has established world class target identification and validation capabilities based on gene knock out technology and in vivo pharmacology. The acquisition of Amedis Pharmaceuticals in January 2005 added key medicinal chemistry skills.
The combined company has focused on the identification of novel, small molecule tractable targets with defined therapeutic utility within key gene families such as G-protein coupled receptors (GPCRs), ion channels and proteases. The company has developed a drug discovery pipeline comprising targets and late stage pre-clinical projects in key areas of unmet medical need in pain, CNS disorders, hormone dependent diseases such as prostate and breast cancer and metabolic diseases such as diabetes, hyperlipidemias, obesity and osteoporosis.
In June 2005 Paradigm Therapeutics announced two major collaborations with Ortho-McNeil Pharmaceuticals (J&J) in pain and urinary urge incontinence and with Takeda in CNS disorders. The company is based in Cambridge and Singapore.
STOP PRESS:Takeda Pharmaceutical Co Ltd acquired Paradigm Therapeutics Ltd for an undisclosed sum in March 2007 and renamed it Takeda Cambridge Ltd.
Staff
Contact details
CAMBRIDGE
CB4 0GP
United Kingdom
